Alzheimer’s disease is slowed by a new drug
Eli Lilly, a drug company, reports that donanemab has the potential to slow down Alzheimer’s by 35% following a human Phase 3 study.
Images of brain scans from Alzheimer’s patients treated with A and B and a placebo (c) showing the clearance of amyloid deposits. Credit: Eli Lilly.
Alzheimer’s disease has been a major issue in public health over the past few years. This disease, a progressive neurodegenerative disorder that affects thinking, memory and behavior, is on the rise due to aging populations, lifestyle changes and improved diagnostic techniques.
Source:
https://www.futuretimeline.net/blog/2023/05/7-alzheimer-future-predictions.htm
